

# 1. AZATHIOPRINE

*Ma. Fredelita C. Asuncion, MD*

## **Introduction**

Azathioprine (AZA) is an antagonist of purine metabolism, which inhibits DNA, RNA and protein synthesis. It is an immunosuppressive agent used for the treatment of rheumatic diseases, inflammatory bowel diseases and the prevention of organ transplant rejection.

## **Mechanism of Action**

Azathioprine is a prototypic immunosuppressive antimetabolite. It is a prodrug of mercaptopurine that is well-absorbed from the gastrointestinal (GI) tract. Azathioprine is cleaved by xanthine oxidase to 6-thiouric acid.<sup>1-2</sup>

Once metabolized, azathioprine exerts its immunosuppressive effects by inhibition of purine and protein synthesis in lymphocytes.<sup>3</sup> This reduction in intracellular purine synthesis inhibits the proliferation of T and B lymphocytes, leading to decreased production of cytotoxic T lymphocytes and plasma cells, reduced immunoglobulin synthesis<sup>4</sup> and diminished interleukin (IL)-2 secretion.<sup>5</sup> AZA does not reduce serum levels of IL-6 or soluble IL-2 receptor.<sup>6</sup>

So far, there are no articles indicating the potential of Azathioprine in suppressing COVID-19 cytokine storm.

## **Clinical Studies**

Currently, there are no clinical trials on the use of Azathioprine for COVID-19.

## **Recommended Dose**

No recommended dose as of yet.

## **Adverse Effects**

The most common side effects of AZA at doses typically used in the treatment of rheumatic diseases include gastrointestinal intolerance<sup>2</sup>, bone marrow suppression<sup>7</sup>, and infection.<sup>8-9</sup>

The major side effects include dose-dependent myelosuppression, particularly leukopenia. Azathioprine should be temporarily withheld if the white cell count falls below 3000/mm<sup>3</sup> or drops by 50 percent compared with the previous value. Other potentially serious side effects include hepatotoxicity and pancreatitis.

## **Conclusion**

There is no available evidence as to the use of Azathioprine in COVID-19.

## **REFERENCES:**

1. Elion GB, Hitchings GH. Azathioprine. *Handbook Exp Pharmacol* 1975; 38:404.
2. Huskisson EC. Azathioprine. *Clin Rheum Dis* 1984; 10:325.
3. McKendry RJR. Purine analogues. In: *Second Line Agents in the Treatment of Rheumatic Diseases*, Dixon J, Furst BE (Eds), Marcel Decker, New York 1991.
4. Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. *N Engl J Med* 1982; 306:365.
5. Bacon PA, Salmon M. Modes of action of second-line agents. *Scand J Rheumatol Suppl* 1987; 64:17.
6. Crilly A, McInnes IB, Capell HA, Madhok R. The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor. *Scand J Rheumatol* 1994; 23:87.
7. Bacon PA, Salmon M. Modes of action of second-line agents. *Scand J Rheumatol Suppl* 1987; 64:17.
8. Pinals RS. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. *J Rheumatol* 1976; 3:140.
9. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. *Arthritis Rheum* 1989; 32:837